Inflammopharmacology
Journal metrics
Annual Clarivate and SCImago indicators.
| Year | JCR | SJR | ||||
|---|---|---|---|---|---|---|
| IF | IF quartile | Rank (percentile) | SJR | SJR quartile | Rank (percentile) | |
| 2025 | 6.3 | Q1 | 90.6% | 1.373 | Q1 | 90.6% |
| 2024 | 5.3 | Q1 | 88.7% | 1.269 | Q1 | 89.5% |
| 2023 | 4.6 | Q1 | 84.5% | 0.952 | Q1 | 84.3% |
| 2022 | 5.8 | Q1 | 88.8% | 0.932 | Q1 | 84.6% |
| 2021 | 5.1 | Q1 | 81.4% | 0.772 | Q2 | 80.1% |
| 2020 | — | — | 0.945 | Q2 | 84.0% | |
| 2019 | — | — | 0.729 | Q2 | 77.9% | |
| 2018 | — | — | 0.894 | Q2 | 81.5% | |
Impact history
Annual SJR and Impact Factor trend.
SJRIF
Journal record
eISSN
1568-5608
ISSN
0925-4692
country
CHcoverage
1991-2026